









Markets
/
Stocks
/
nasdaq-nktx
/

Nkarta Inc

NKTX

2.000USD

-0.060-2.91%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

60.86MMarket Cap

LossP/E TTM



Nkarta Inc

2.000

-0.060-2.91%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Nkarta Inc

Currency: USD Updated: 2026-03-30

Key Insights

Nkarta Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 78 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nkarta Inc's Score

Industry at a Glance

Industry Ranking

78 / 391

Overall Ranking

196 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Nkarta Inc Highlights

StrengthsRisks

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

Fairly Valued

The company’s latest PE is -1.42, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 60.95M shares, decreasing 27.71% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 140.88K shares of this stock.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

13.000

Target Price

+531.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-30

The current financial score of Nkarta Inc is 5.46, ranking 360 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.46

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Nkarta Inc's Company Valuation

Currency: USD Updated: 2026-03-30

The current valuation score of Nkarta Inc is 8.53, ranking 40 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.42, which is -63.16% below the recent high of -0.52 and -360.92% above the recent low of -6.55.

Score

Industry at a Glance

Previous score

8.53

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 78/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-30

The current earnings forecast score of Nkarta Inc is 8.29, ranking 139 out of 391 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 16.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.67

Change

-0.38

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

13.000

Target Price

+531.07%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Nkarta Inc

NKTX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-30

The current price momentum score of Nkarta Inc is 6.62, ranking 172 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.55 and the support level at 1.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.64

Change

-0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.083

Sell

RSI(14)

36.979

Neutral

STOCH(KDJ)(9,3,3)

14.918

Oversold

ATR(14)

0.139

Low Volatility

CCI(14)

-143.057

Sell

Williams %R

93.333

Oversold

TRIX(12,20)

-0.490

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.076

Sell

MA10

2.143

Sell

MA20

2.305

Sell

MA50

2.282

Sell

MA100

2.082

Sell

MA200

2.075

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-30

The current institutional shareholding score of Nkarta Inc is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 85.81%, representing a quarter-over-quarter decrease of 0.39%. The largest institutional shareholder is The Vanguard, holding a total of 2.60M shares, representing 3.64% of shares outstanding, with 2.38% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

10.81M

New Enterprise Associates (NEA)

3.57M

Samsara BioCapital, LLC

3.51M

-6.91%

BlackRock Institutional Trust Company, N.A.

3.21M

-12.13%

SR One Capital Management, LP

3.33M

GSK plc

3.16M

EQT Life Sciences

2.84M

The Vanguard Group, Inc.

Star Investors

2.49M

-2.45%

Monaco asset management S.A.M.

1.97M

+24.48%

Alyeska Investment Group, L.P.

2.08M

Risk Assessment

Currency: USD Updated: 2026-03-30

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Nkarta Inc is 3.79, ranking 119 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Nkarta Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.